

FITC anti-mouse CD8a Antibody

Catalog# / Size	100705 / 50 µg 100706 / 500 µg
Clone	53-6.7
Regulatory Status	RUO
Other Names	T8, Lyt2, Ly-2
Isotype	Rat IgG2a, κ
Description	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse thymus or spleen
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm)
Application Notes	Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes ³ . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a ⁺ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation ^{1,3} , <i>in vivo</i> and <i>in vitro</i> cell depletion ^{2,10,15} , inhibition of CD8 T cell proliferation ³ , blocking of cytotoxicity ^{3,4} , immunohistochemical staining ^{5,6} of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX) ^{29,30} . Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or <i>in vivo</i> studies (Cat No. 100746).
Application References	<ol style="list-style-type: none"> 1. Ledbetter JA, <i>et al.</i> 1979. <i>Immunol. Rev.</i> 47:63. (IHC, IP) 2. Hathcock KS. 1991. <i>Current Protocols in Immunology</i>. 3.4.1. (Deplete) 3. Takahashi K, <i>et al.</i> 1992. <i>P. Natl. Acad. Sci. USA</i> 89:5557. (Block, IP) 4. Ledbetter JA, <i>et al.</i> 1981. <i>J. Exp. Med.</i> 153:1503. (Block)
(PubMed link indicates BioLegend citation)	

5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, *et al.* 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, *et al.* 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, *et al.* 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, *et al.* 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, *et al.* 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, *et al.* 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, *et al.* 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, *et al.* 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, *et al.* 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, *et al.* 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, *et al.* 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, *et al.* 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, *et al.* 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Sun L, *et al.* 2021. *Cancer Cell.* .: [PubMed](#)
2. Logan K Smith *et al.* 2018. *Immunity.* 48(2):299-312 . [PubMed](#)
3. Liu J, *et al.* 2019. *Immunity.* 50:600. [PubMed](#)
4. Strickley JD, *et al.* 2019. *Nature.* 575:519. [PubMed](#)
5. Dong MB, *et al.* 2020. *Cell.* 178(5):1189-1204.e23.. [PubMed](#)
6. Petrova T, *et al.* 2020. *Sci Rep.* 10:3479. [PubMed](#)
7. Xiang G, *et al.* 2022. *Cell Death Dis.* 13:451. [PubMed](#)
8. Wu MJ, *et al.* 2022. *Cancer Discov.* 12:812. [PubMed](#)
9. Yao RQ, *et al.* 2022. *Theranostics.* 12:4606. [PubMed](#)
10. Gerwing M, *et al.* 2020. *Mol Imaging Biol.* 1.959027778. [PubMed](#)
11. Han X, *et al.* 2017. *Int J Mol Sci.* 10.3390/ijms18050942. [PubMed](#)
12. Furuta Y, *et al.* 2017. *PLoS One.* 12(2):e0172509. [PubMed](#)
13. Kawano H, *et al.* 2016. *Int Immunol.* 28: 489 - 501. [PubMed](#)
14. Liu W, *et al.* 2020. *Mol Ther Oncolytics.* 17:350. [PubMed](#)
15. Lin W, *et al.* 2020. *Theranostics.* 10:4871. [PubMed](#)
16. Yang H, *et al.* 2019. *Mol Metab.* 23:24. [PubMed](#)
17. Taddeo A, *et al.* 2022. *NPJ Vaccines.* 7:82. [PubMed](#)
18. Schönberger K, *et al.* 2022. *Cell Stem Cell.* 29:131. [PubMed](#)
19. Paschall A, *et al.* 2015. *J Immunol.* 194: 2369-2379. [PubMed](#)
20. Zhang Y, *et al.* 2020. *Oncol Lett.* 1.053472222. [PubMed](#)
21. Ren S, *et al.* 2019. *Oncol Rep.* 41:1509. [PubMed](#)
22. Lee H, *et al.* 2020. *Cell Metabolism.* 31(4):822-836. [PubMed](#)
23. Seo YB, *et al.* 2021. *Vaccines (Basel).* 9: . [PubMed](#)
24. Zhang J, *et al.* 2021. *MedComm (Beijing).* 2:256. [PubMed](#)
25. Altshuler A, *et al.* 2021. *Cell Stem Cell.* 28(7):1248-1261.e8. [PubMed](#)
26. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
27. Hao B, *et al.* 2015. *J Exp Med.* 212:809. [PubMed](#)
28. Apte S, *et al.* 2010. *J Immunol.* 185:998. [PubMed](#)
29. Gotoh K *et al.* 2018. *Cell reports.* 25(7):1800-1815 . [PubMed](#)
30. Mayer RL, *et al.* 2022. *Nat Commun.* 13:6075. [PubMed](#)
31. Yang X, *et al.* 2020. *Blood Sci.* 2:89. [PubMed](#)
32. Wang Q, *et al.* 2020. *Wound Repair Regen.* 28:105. [PubMed](#)
33. Castellanos CA, *et al.* 2021. *Sci Immunol.* 6:eabh0707. [PubMed](#)
34. Morales D, *et al.* 2015. *J Virol.* 89:337. [PubMed](#)
35. Wang Y, *et al.* 2016. *Sci Rep.* 6:31881. [PubMed](#)
36. Lutes LK, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
37. Okamoto T, *et al.* 2020. *Cancer Res.* 3580:80. [PubMed](#)
38. Wang X, *et al.* 2021. *Front Cell Dev Biol.* 632805:9. [PubMed](#)
39. Luff DH, *et al.* 2021. *Front Immunol.* 631271:12. [PubMed](#)
40. Antonia O Cuff *et al.* 2017. *Wellcome open research.* 2:39 . [PubMed](#)
41. Pham THM, *et al.* 2020. *Cell Host & Microbe.* 27(1):54-67.e5.. [PubMed](#)
42. Treger RS, *et al.* 2020. *Immunity.* 50(2):334-347.e9.. [PubMed](#)
43. Yoon Y, *et al.* 2021. *Cancers (Basel).* 13: . [PubMed](#)
44. Shi S, *et al.* 2020. *Clin Cancer Res.* 26:5990. [PubMed](#)
45. Wang Y, *et al.* 2022. *Acta Pharm Sin B.* 12:262. [PubMed](#)
46. Wu K, *et al.* 2021. *Aging (Albany NY).* 13: . [PubMed](#)
47. Mukherjee D, *et al.* 2022. *Nat Commun.* 13:3747. [PubMed](#)
48. Xiong A, *et al.* 2022. *EBioMedicine.* 83:104239. [PubMed](#)
49. Tu X, *et al.* 2022. *Nat Commun.* 13:6977. [PubMed](#)
50. Magod P, *et al.* 2021. *Cell Reports.* 36(5):109480. [PubMed](#)
51. Mitchell JE, *et al.* 2021. *Cell Reports.* 35(2):108966. [PubMed](#)

52. Lv H, *et al.* 2020. *Cell Metabolism*. 33(1):110-127.e5. [PubMed](#)
53. Artinger K, *et al.* 2015. *PLoS One*. 10: 0135087. [PubMed](#)
54. Shade K, *et al.* 2015. *J Exp Med*. 212:457. [PubMed](#)
55. DeBerge M, *et al.* 2013. *PLoS One*. 8:79340. [PubMed](#)
56. Uchimura T *et al.* 2018. *Immunity*. 49(6):1049-1061 . [PubMed](#)
57. Dodagatta-Marri E, *et al.* 2021. *Cell Rep*. 36:109309. [PubMed](#)
58. Suah AN, *et al.* 2021. *J Clin Invest*. 131:. [PubMed](#)
59. Cousin N, *et al.* 2021. *Cancer Res*. 81:4133. [PubMed](#)
60. Nicolay N, *et al.* 2016. *Sci Rep*. 6: 26645. [PubMed](#)
61. Velázquez K, *et al.* 2016. *Am J Physiol Gastrointest Liver Physiol*. 311: G699 - G712. [PubMed](#)
62. Zhang F, *et al.* 2019. *Immunity*. 50:738. [PubMed](#)
63. Wang F, *et al.* 2021. *Cell Mol Gastroenterol Hepatol*. 13:257. [PubMed](#)
64. MacDonald A, *et al.* 2021. *Front Immunol*. 12:755995. [PubMed](#)
65. Zebley CC, *et al.* 2021. *Cell Rep*. 37:109796. [PubMed](#)
66. Köchl R, *et al.* 2020. *Elife*. 9:00. [PubMed](#)
67. Len-Letelier RA, *et al.* 2020. *Frontiers in Immunology*. 11:583382. [PubMed](#)
68. Maluski M, *et al.* 2019. *J Clin Invest*. 129:5108. [PubMed](#)
69. Xiao P, *et al.* 2019. *J Exp Med*. 216:337. [PubMed](#)
70. Topper MJ *et al.* 2017. *Cell*. 171(6):1284-1300 . [PubMed](#)
71. Li Y, *et al.* 2019. *Sci Rep*. 9:6932. [PubMed](#)
72. Wu L, *et al.* 2022. *Theranostics*. 12:842. [PubMed](#)
73. Gu Y, *et al.* 2021. *Cell Res*. Online ahead of print. [PubMed](#)
74. Zhang B, *et al.* 2021. *Nat Biomed Eng*. 5:1288. [PubMed](#)
75. Wu J, *et al.* 2020. *Immunity*. 53:115. [PubMed](#)
76. Aebischer D, *et al.* 2014. *PLoS One*. 9:99297. [PubMed](#)
77. Drees J, *et al.* 2015. *Anticancer Res*. 35:843. [PubMed](#)
78. Lu X, *et al.* 2016. *Nat Commun*. 7: 12719. [PubMed](#)
79. Xie Z, *et al.* 2020. *Light Sci Appl*. 0.486805556. [PubMed](#)
80. Li Y, *et al.* 2020. *Cell Stem Cell*. 27(5):732-747.e7. [PubMed](#)
81. Crowe JL, *et al.* 2020. *Proc Natl Acad Sci U S A*. 22953:117. [PubMed](#)
82. Webster P, *et al.* 2018. *Nat Commun*. 9:2649. [PubMed](#)
83. Niemann J, *et al.* 2019. *Nat Commun*. 10:3236. [PubMed](#)
84. Srivastava S, *et al.* 2019. *Cancer Cell*. 35:489. [PubMed](#)
85. Wu Y, *et al.* 2021. *Nat Commun*. 12:2346. [PubMed](#)
86. Pishesha N, *et al.* 2021. *Proc Natl Acad Sci U S A*. 118:. [PubMed](#)
87. Volberding PJ, *et al.* 2021. *Cell Reports*. 35(8):109160. [PubMed](#)
88. Tacconi C, *et al.* 2021. *Cell Reports*. 35(2):108993. [PubMed](#)
89. Yang J, *et al.* 2020. *Nature*. 586:572. [PubMed](#)
90. Knocke S, *et al.* 2016. *Cell Rep*. 17:2234-2246. [PubMed](#)
91. Ito C, *et al.* 2015. *PLoS One*. 10: e0140808. [PubMed](#)
92. Wu S, *et al.* 2014. *Clin Vaccine Immunol*. 21:156. [PubMed](#)
93. Wan X, *et al.* 2018. *Nature*. 560:107. [PubMed](#)
94. Qi S *et al.* 2016. *eLife*. 5 pii: e14756. [PubMed](#)
95. Budida R, *et al.* 2017. *Eur J Immunol*. 47:1819. [PubMed](#)
96. Kim JH, *et al.* 2019. *Mol Med*. 25:33. [PubMed](#)
97. Ren Y, *et al.* 2022. *J Immunother Cancer*. 10: [PubMed](#)
98. Trefzer A, *et al.* 2021. *Cell Reports*. 34(6):108748. [PubMed](#)
99. Vaena S, *et al.* 2021. *Cell Reports*. 35(5):109076. [PubMed](#)
100. Fang Y, *et al.* 2019. *Aging (Albany NY)*. 11:4910. [PubMed](#)
101. Horkova V, *et al.* 2020. *Cell Reports*. 30(5):1504-1514.e7.. [PubMed](#)
102. Du J, *et al.* 2018. *AMB Express*. 8:158. [PubMed](#)
103. Holman P, *et al.* 2005. *J Immunol*. 174:3986. [PubMed](#)
104. Huang Z, *et al.* 2021. *Nat Commun*. 12:145. [PubMed](#)
105. Grioni M, *et al.* 2021. *Blood Adv*. 5:2817. [PubMed](#)
106. Matundan HH, *et al.* 2021. *J Virol*. 95:e0103621. [PubMed](#)
107. Bosnjak B, *et al.* 2021. *Front Immunol*. 12:772240. [PubMed](#)
108. Sun C, *et al.* 2022. *J Adv Res*. 35:71. [PubMed](#)
109. Dey S, *et al.* 2020. *J Immunother Cancer*. 8: [PubMed](#)
110. Zheng D, *et al.* 2022. *Acta Pharm Sin B*. 12:2740. [PubMed](#)
111. Liu B, *et al.* 2022. *Mol Med Rep*. 26:. [PubMed](#)
112. Nikolos F, *et al.* 2022. *Nat Commun*. 13:1487. [PubMed](#)
113. Yan J, *et al.* 2020. *Cell Rep*. 107820:31. [PubMed](#)
114. Yi W, *et al.* 2021. *Cell Reports*. 34(13):108922. [PubMed](#)
115. Shen JZ, *et al.* 2020. *Cell*. 184(2):352-369.e23. [PubMed](#)
116. Li X, *et al.* 2020. *Nat Commun*. 4.877777778. [PubMed](#)
117. Denny JE, *et al.* 2019. *Sci Rep*. 2.786111111. [PubMed](#)
118. Landon J Edgar *et al.* 2018. *Cell chemical biology*. 26(1):131-136 . [PubMed](#)
119. Chatterjee S *et al.* 2017. *Cell metabolism*. 27(1):85-100 . [PubMed](#)
120. Wang R, *et al.* 2022. *Front Immunol*. 13:947756. [PubMed](#)
121. Jin C, *et al.* 2022. *Oncoimmunology*. 11:2099642. [PubMed](#)
122. Frost JN, *et al.* 2021. *Med (N Y)*. 2:164. [PubMed](#)
123. Daneshmandi S, *et al.* 2021. *Elife*. 10:. [PubMed](#)
124. Huang L, *et al.* 2021. *Breast Cancer Res Treat*. Online ahead of print. [PubMed](#)
125. Wang L, *et al.* 2015. *Cancer Immunol Res*. 3: 1030-1041. [PubMed](#)
126. Li Y, Kaneda T 2016. *Sci Rep*. 6: 25077. [PubMed](#)
127. Perry JL, *et al.* 2020. *ACS Nano*. 5.583333333. [PubMed](#)
128. Blagih J, *et al.* 2020. *Cell Rep*. 30:481. [PubMed](#)
129. Fu S, *et al.* 2020. *Nat Commun*. 0.7625. [PubMed](#)
130. Tao Z, *et al.* 2019. *Clin Cancer Res*. 25:1113. [PubMed](#)
131. Zhang NN, *et al.* 2020. *Cell*. 182(5):1271-1283. [PubMed](#)

132. Bartolacci C, *et al.* 2018. *Cancer Immunol Res.* 1.281944444. [PubMed](#)
133. Riedl P, *et al.* 2009. *J Immunol.* 183:370. [PubMed](#)
134. Zhan L, *et al.* 2022. *Cancer Lett.* 529:37. [PubMed](#)
135. Tsukui H, *et al.* 2020. *BMC Cancer.* 20:411. [PubMed](#)
136. Chen R, *et al.* 2021. *Cell Reports.* 34(7):108751. [PubMed](#)
137. Kvell K, *et al.* 2014. *Immunobiology.* 219:644. [PubMed](#)
138. Dulken BW, *et al.* 2019. *Nature.* 571:205. [PubMed](#)
139. Hu Z, *et al.* 2020. *PLoS One.* 15:e0228339. [PubMed](#)
140. Ibrahim ML, *et al.* 2018. *Cell Rep.* 25:3036. [PubMed](#)
141. Feng D, *et al.* 2022. *Nat Commun.* 13:5554. [PubMed](#)
142. He C, *et al.* 2022. *Nat Commun.* 13:5459. [PubMed](#)
143. Li M, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
144. Berghoff SA, *et al.* 2021. *Nat Neurosci.* 24:47. [PubMed](#)
145. Fang F, *et al.* 2021. *Cell Rep.* 37:109981. [PubMed](#)
146. Shen L, *et al.* 2015. *Cancer Immunol Res.* 3:136. [PubMed](#)
147. Calderon B, *et al.* 2015. *J Exp Med.* 212: 1497-1512. [PubMed](#)
148. Yasuma K, *et al.* 2016. *PLoS Pathog.* 12: 1005372. [PubMed](#)
149. Martina M, *et al.* 2016. *J Am Soc Nephrol.* 27: 1113-1123. [PubMed](#)
150. Miura N, *et al.* 2017. *Mol Ther.* 10.1016/j.ymthe.2017.01.020. [PubMed](#)
151. Daneshmandi S, *et al.* 2021. *Cell Reports.* 34(10):108831. [PubMed](#)
152. Xia Y, *et al.* 2018. *Cell.* 175:1059. [PubMed](#)
153. Urata S, *et al.* 2018. *PLoS Pathog.* 14:e1007172. [PubMed](#)
154. Raju S, *et al.* 2020. *Cell Reports.* 29(9):2556-2564.e3.. [PubMed](#)
155. Panigrahy D, *et al.* 2019. *J Clin Invest.* 130:2964. [PubMed](#)
156. Wu P, *et al.* 2020. *Cancer Immunol Res.* 8:1470. [PubMed](#)
157. Soria-Castro R, *et al.* 2020. *Sci Rep.* 10:17802. [PubMed](#)
158. Roderick J, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:14436. [PubMed](#)
159. Kos S, *et al.* 2019. *PLoS One.* 14:e0217762. [PubMed](#)
160. Li Q, *et al.* 2022. *Front Oncol.* 12:841977. [PubMed](#)
161. Kung YJ, *et al.* 2022. *J Biomed Sci.* 29:57. [PubMed](#)
162. Leary N, *et al.* 2022. *J Extracell Vesicles.* 11:e12197. [PubMed](#)
163. Ren Y, *et al.* 2021. *Nat Commun.* 12:5405. [PubMed](#)
164. Porrello A, *et al.* 2018. *Nat Commun.* 9:1988. [PubMed](#)
165. Sade-Feldman M, *et al.* 2018. *Cell.* 175:998. [PubMed](#)
166. Golan K *et al.* 2018. *Cell stem cell.* 23(4):572-585 . [PubMed](#)
167. Sivapatham S, *et al.* 2019. *Front Immunol.* 1.865277778. [PubMed](#)
168. Royzman D, *et al.* 2019. *Front Immunol.* 10:633. [PubMed](#)
169. Tsyklauri O, *et al.* 2021. *EMBO Rep.* 22:e50785. [PubMed](#)
170. Petriv N, *et al.* 2021. *Oncoimmunology.* 10:1874159. [PubMed](#)
171. Kim S, *et al.* 2022. *Cancers (Basel).* 14:. [PubMed](#)
172. Zhang Z, *et al.* 2020. *Nature.* 579:415. [PubMed](#)
173. Cané S, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
174. Chakraborty P, *et al.* 2020. *Cell Reports.* 28(7):1879-1893.e7.. [PubMed](#)
175. Fleskens V, *et al.* 2019. *Cell Rep.* 26:3600. [PubMed](#)
176. Li K, *et al.* 2020. *Nat Commun.* 0.795138889. [PubMed](#)
177. Burton OT, *et al.* 2018. *Clin Exp Allergy.* 48:288. [PubMed](#)
178. Chryplewicz A, *et al.* 2022. *Cancer Cell.* 40:1111. [PubMed](#)
179. Li X, *et al.* 2022. *Oncoimmunology.* 11:2118210. [PubMed](#)
180. Li H, *et al.* 2022. *iScience.* 25:104481. [PubMed](#)
181. Wang X, *et al.* 2022. *Elife.* 11:. [PubMed](#)
182. D'Cruz L, *et al.* 2014. *J Immunol.* 192:2227. [PubMed](#)
183. Katsuyama T, *et al.* 2021. *Cell Reports.* 36(1):109339. [PubMed](#)
184. Wu L, *et al.* 2020. *Cancer Immunol Res.* 710:8. [PubMed](#)
185. Su M, *et al.* 2018. *Immunol Cell Biol.* 9:2448. [PubMed](#)
186. Hebbandi Nanjundappa R, *et al.* 2017. *Cell.* 171:655. [PubMed](#)
187. Tanegashima K *et al.* 2017. *EBioMedicine.* 24:247-256 . [PubMed](#)
188. Hong Y, *et al.* 2019. *J Extracell Vesicles.* 8:1670893. [PubMed](#)
189. Kim YS, *et al.* 2018. *Front Immunol.* 9:1093. [PubMed](#)
190. Wen X, *et al.* 2021. *World J Gastroenterol.* 27:2834. [PubMed](#)
191. Wang K, *et al.* 2021. *Nat Commun.* 12:4558. [PubMed](#)
192. Xie L, *et al.* 2020. *Infect Immun.* :88. [PubMed](#)
193. Hayashi K, *et al.* 2020. *Nat Commun.* 4.832638889. [PubMed](#)
194. Schlecker E, *et al.* 2012. *J Immunol.* 189:5602. [PubMed](#)
195. Zhi Y, *et al.* 2020. *Int J Mol Med.* 45:1327. [PubMed](#)
196. Bing Wu *et al.* 2018. *Immunity.* 49(5):886-898 . [PubMed](#)
197. Li CY, *et al.* 2022. *Int J Mol Sci.* 23:. [PubMed](#)
198. Ying B, *et al.* 2022. *Sci Transl Med.* 14:eabm3302. [PubMed](#)
199. Lee S, *et al.* 2021. *Autophagy.* Online ahead of print. [PubMed](#)
200. Song X, *et al.* 2022. *Transl Oncol.* 15:101306. [PubMed](#)
201. Akhtar MN, *et al.* 2020. *PLoS Pathog.* 16:e1009136. [PubMed](#)
202. Xie Z, *et al.* 2020. *Light Sci Appl.* 9:161. [PubMed](#)
203. Gu Z, *et al.* 2021. *Nat Genet.* 53:672. [PubMed](#)
204. Yang F, *et al.* 2021. *Nat Commun.* 12:3424. [PubMed](#)

RRID

AB_312744 (BioLegend Cat. No. 100705)

AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure	Ig superfamily, CD8 α chain, 34 kD
Distribution	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function	Co-receptor for TCR
Ligand/Receptor	MHC class I molecule
Antigen References	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. <i>Immunity</i> 1:243. 3. Ellmeier W, <i>et al.</i> 1999. <i>Annu. Rev. Immunol.</i> 17:523.
Gene ID	12525


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GoInVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a

Product Data



C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587